CARL ZEISS MEDITEC AG (FRA:AFX) EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.

Transparency directive : regulatory news

15/12/2023 17:43

EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Takeover/Mergers & Acquisitions
Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.

15-Dec-2023 / 17:43 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.

Jena, December 15, 2023

Carl Zeiss Meditec AG (ISIN: DE0005313704) announces today that it has entered into a definitive agreement to acquire 100% of the shares in Dutch Ophthalmic Research Center (International) BV, Zuidland, Netherlands (D.O.R.C.), from the investment firm Eurazeo SE, Paris, France (ISIN: FR0000121121). D.O.R.C. is a leading company in the vitreo-retinal surgery segment with close to EUR 200 million in revenue expected in fiscal 2023 and an operating profit in the mid double digit million EUR range. The acquisition will enhance and compliment Carl Zeiss Meditec’s ophthalmic portfolio for addressing a wide variety of eye conditions, including retinal disorders, cataracts, glaucoma and refractive errors.

The acquisition is expected to close in the first half of calendar year 2024 subject to applicable regulatory and antitrust approvals. The transaction is valued at an enterprise value of approximately EUR 985 million. The purchase price will be paid for primarily by available net liquidity of Carl Zeiss Meditec AG. In order to maintain operational flexibility, the company plans to seek a shareholder loan from Carl Zeiss AG in the amount of EUR 400 million as part of the financing, with a duration of three years and market-standard conditions.

The acquisition should achieve a modest positive contribution (by a single digit percentage amount) to the earnings per share of Carl Zeiss Meditec AG in the first full year after closing.

Contact for investors and press

Sebastian Frericks

Head of Group Finance & Investor Relations

Carl Zeiss Meditec AG

Tel.: +49 3641 220-116

E-Mail: investors.meditec@zeiss.com

End of Inside Information

15-Dec-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Carl Zeiss Meditec AG
	Göschwitzer Str. 51-52
	07745 Jena, Germany
	Germany
Phone:	+49 (0)3641 220-0
Fax:	+49 (0)3641 220-112
E-mail:	investors.meditec@zeiss.com
Internet:	www.zeiss.de/meditec-ag/ir
ISIN:	DE0005313704
WKN:	531370
Indices:	MDAX, TecDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1798059


End of Announcement	EQS News Service

1798059 15-Dec-2023 CET/CEST

CARL ZEISS MEDITEC AG's latest news

09/02/2024 07:00

CARL ZEISS MEDITEC AG (FRA:AFX) EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.

Transparency directive : regulatory news

CARL ZEISS MEDITEC AG's latest news

Other stories